Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2001

View Archived Issues

FDA accepts Estrasorb NDA for review

Vertex and Array BioPharma establish small-molecule drug discovery agreement

Joint Onco TCS clinical development program expanded

Results presented on CryoLife's cancer treatment drug delivery system

Topiglan development continues to move forward

FDA grants fast track designation for Repligen's secretin

Clinical trial of Cur-61414 commences for treatment of sporadic BCC

A new anxioselective compound --SL-65.1498-- characterized

Orally active DP receptor antagonist prevents allergic inflammation in guinea pigs

FXV-673, a new factor Xa inhibitor, compares favorably to heparin in canine thrombosis model

SAR in a series of glycine derivatives results in discovery of selective hGlyT-1b inhibitor

Proof of concept established in phase II trials for NN-622

Therapeutic vaccine for nicotine addiction enters clinical testing

Cell Genesys completes Calydon acquisition

FDA panel emits positive recommendation for Zevalin

Targeted apoptosis research program at Antisoma expanded by newly acquired rights from NIH

Long-term clinical data favor rosuvastatin over other statins in hypercholesterolemia

Novartis, QLT seek approval for expanded use of Visudyne in E.U.

Amiodarone metabolite has similar long-term electrophysiological effects in dogs

Selective cathepsin K inhibitors synthesized and tested at Roche

Celltech patent reveals alpha4 integrin-inhibitory squaric acid derivatives

Bayer presents new integrin inhibitors, uses and pharmaceutical compositions

Piperidine- and piperazine-based P2X7 receptor antagonists designed at AstraZeneca

Antiscarring PCP inhibitors in the Pfizer pipeline

Novuspharma antitumor agents particularly effective against solid tumors

LGD-2226 selected as clinical candidate SARM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...